AI Article Synopsis

  • Laparoscopic cholecystectomy patients often experience postoperative nausea and vomiting (PONV), prompting a study to assess if combining granisetron with dexamethasone is more effective than using granisetron alone.
  • In a randomized trial, 120 patients received either granisetron or the combination treatment before surgery, with results measured over 24 hours post-op.
  • The combination treatment significantly improved the complete response rate (95% vs. 83%) and reduced the incidence of PONV (5% vs. 18.3%), suggesting its clinical relevance for patients at high risk of PONV.

Article Abstract

Background: Laparoscopic cholecystectomies are associated with an appreciably high rate of postoperative nausea and vomiting (PONV). This study was designed to compare the effectiveness of granisetron plus dexamethasone with granisetron alone for the prevention of postoperative nausea and vomiting in patients after laparoscopic cholecystectomy.

Methods: In a randomized, double-blind study, 120 patients of both sexes received granisetron 40 micro g kg-1 alone or granisetron 40 micro g kg-1 plus dexamethasone 8 mg (n=60 of each) intravenously immediately before induction of anesthesia. Perioperative anesthetic care was standardized in all patients. Patients were then observed for 24 h after administration of the study drug.

Results: A complete response (defined as no PONV and no need for another rescue antiemetic) was achieved in 83% of the patients given granisetron and in 95% of the patients given granisetron plus dexamethasone (P<0.05). The overall cumulative incidences (0-24 h) of PONV were 11 (18.3%) in the granisetron and three (5%) in the combination group. No difference in adverse events were observed in any of the groups.

Conclusion: The combination (granisetron plus dexamethasone) further increases the chance of complete response than granisetron alone. Therefore, the combination might be considered clinically relevant in a high risk setting.

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1399-6576.2003.470114.xDOI Listing

Publication Analysis

Top Keywords

granisetron dexamethasone
12
postoperative nausea
12
nausea vomiting
12
prevention postoperative
8
granisetron micro
8
micro kg-1
8
patients granisetron
8
granisetron
7
patients
6
comparison granisetron
4

Similar Publications

Article Synopsis
  • Nausea and vomiting during awake craniotomy can lead to serious complications, prompting the use of 5-HT3 receptor antagonists like granisetron and dexamethasone to prevent these issues.* -
  • A study involving 170 patients examined the effectiveness of dexamethasone compared to granisetron in reducing nausea after AC, focusing on a subset of 82 patients matched for analysis.* -
  • Results showed that dexamethasone significantly reduced the incidence of nausea (9.8%) compared to granisetron (41.5%), indicating that dexamethasone is a more effective option for managing nausea during these procedures.*
View Article and Find Full Text PDF

Transcutaneous Pericardium 6 Acupoint Electrical Stimulation Provides Comparable Antiemetic Effect to Granisetron When Combined With Dexamethasone in Patients Undergoing Breast Cancer Surgery.

J Surg Res

November 2024

Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address:

Introduction: Perioperative transcutaneous pericardium 6 (P6) electrical stimulation is effective for prevention of postoperative nausea and vomiting (PONV). The patients undergoing breast cancer surgery have a high PONV prevalence; however, the effectiveness of P6 stimulation in this surgical population has not been investigated.

Materials And Methods: A total of 198 patients undergoing mastectomy under general anesthesia were enrolled.

View Article and Find Full Text PDF

Introduction: We compared the efficacy of first-generation granisetron and second-generation palonosetron in triplet anti-emetic prophylaxis in patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based high emetogenic chemotherapy (HEC).

Methods: This prospective, multicenter, non-randomized, observational study was conducted between June 2018 and December 2021. Patients diagnosed with NSCLC who received triplet anti-emetic prophylactic treatment with aprepitant and dexamethasone plus granisetron or palonosetron before the first cycle of chemotherapy were included in the study.

View Article and Find Full Text PDF

Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting.

BMC Cancer

July 2024

Department of Integrated Traditional & Western Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, China.

Objective: To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving Capecitabine plus Oxaliplatin (CapeOX) therapy.

Design: Open-label, prospective, multi-center phase II trial.

Setting: Three institutions.

View Article and Find Full Text PDF

Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial.

Lung Cancer

June 2024

Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan; Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu, Gifu, 501-1196, Japan. Electronic address:

Article Synopsis
  • Mirtazapine, when combined with granisetron and dexamethasone, was studied for preventing nausea and vomiting caused by carboplatin in patients with thoracic cancers.
  • A trial involving 52 patients showed high rates of complete response—83.3% during the delayed phase (24-120 hours) and 100% in the acute phase (0-24 hours)—with minimal side effects.
  • Results suggest that this three-drug combination is effective and safe for patients undergoing chemotherapy with carboplatin at specified dosages.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!